Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 9Terminated 2Withdrawn 1Recruiting 1No longer available 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Classical hematology 1

Conditions

Leukemia, Myeloid, Acute 17Precursor Cell Lymphoblastic Leukemia-Lymphoma 15Lymphoma, Non-Hodgkin 12Myelodysplastic Syndromes 11Recurrence 7Leukemia, Myelomonocytic, Chronic 7Anemia, Refractory, with Excess of Blasts 7Leukemia, Biphenotypic, Acute 6Multiple Myeloma 5Lymphoma, Follicular 5Lymphoma 5Hodgkin Disease 5Hematologic Neoplasms 5Melanoma 4Lymphoma, Large B-Cell, Diffuse 4Leukemia, Myelogenous, Chronic, BCR-ABL Positive 4Burkitt Lymphoma 4Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 3Myeloproliferative Disorders 3Lymphoma, Mantle-Cell 3Lymphoma, B-Cell, Marginal Zone 3Lymphoma, B-Cell 3Leukemia, Lymphocytic, Chronic, B-Cell 3Leukemia 3Breast Neoplasms 3Blastic Plasmacytoid Dendritic Cell Neoplasm 3Uveal Melanoma 2Triple Negative Breast Neoplasms 2Neoplasms, Plasma Cell 2Neoplasms, Germ Cell and Embryonal 2

Interventions

fludarabine phosphate 1Injections 1Idarubicin 1Granulocyte Colony-Stimulating Factor 1Gemtuzumab 1Filgrastim 1Etoposide 1Decitabine 1Cytarabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Leukemia, Myelomonocytic, Acute × fludarabine phosphate × Clear all
NCT00801489 2026-03-30

Fludarabine Phosphate, Cytarabine, Filgrastim-sndz, Gemtuzumab Ozogamicin, and Idarubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

M.D. Anderson Cancer Center

Phase 2 Recruiting
270 enrolled
Classical hematologyOther hematologic neoplasm

Anemia, Refractory, with Excess of Blasts, Leukemia, Myelomonocytic, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡